NO329320B1 - Formulering for behandling av hjerne-, spinal- og nerveskade. - Google Patents
Formulering for behandling av hjerne-, spinal- og nerveskade. Download PDFInfo
- Publication number
- NO329320B1 NO329320B1 NO20023423A NO20023423A NO329320B1 NO 329320 B1 NO329320 B1 NO 329320B1 NO 20023423 A NO20023423 A NO 20023423A NO 20023423 A NO20023423 A NO 20023423A NO 329320 B1 NO329320 B1 NO 329320B1
- Authority
- NO
- Norway
- Prior art keywords
- brain
- magnesium
- substance
- injury
- damage
- Prior art date
Links
- 238000009472 formulation Methods 0.000 title claims description 17
- 239000000203 mixture Substances 0.000 title claims description 17
- 238000011282 treatment Methods 0.000 title claims description 17
- 210000004556 brain Anatomy 0.000 title claims description 14
- 208000028389 Nerve injury Diseases 0.000 title claims description 6
- 230000008764 nerve damage Effects 0.000 title claims description 6
- 230000006378 damage Effects 0.000 claims description 28
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 claims description 17
- 239000011777 magnesium Substances 0.000 claims description 17
- 229910052749 magnesium Inorganic materials 0.000 claims description 17
- DZTHIGRZJZPRDV-LBPRGKRZSA-N N-acetyl-L-tryptophan Chemical compound C1=CC=C2C(C[C@H](NC(=O)C)C(O)=O)=CNC2=C1 DZTHIGRZJZPRDV-LBPRGKRZSA-N 0.000 claims description 15
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 claims description 12
- 229910052943 magnesium sulfate Inorganic materials 0.000 claims description 6
- 235000019341 magnesium sulphate Nutrition 0.000 claims description 6
- 239000000126 substance Substances 0.000 claims description 5
- 239000008280 blood Substances 0.000 claims description 4
- 210000004369 blood Anatomy 0.000 claims description 4
- 208000034693 Laceration Diseases 0.000 claims description 2
- 230000006835 compression Effects 0.000 claims description 2
- 238000007906 compression Methods 0.000 claims description 2
- 210000005036 nerve Anatomy 0.000 claims description 2
- 210000000278 spinal cord Anatomy 0.000 claims description 2
- 208000029028 brain injury Diseases 0.000 description 29
- QDZOEBFLNHCSSF-PFFBOGFISA-N (2S)-2-[[(2R)-2-[[(2S)-1-[(2S)-6-amino-2-[[(2S)-1-[(2R)-2-amino-5-carbamimidamidopentanoyl]pyrrolidine-2-carbonyl]amino]hexanoyl]pyrrolidine-2-carbonyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-N-[(2R)-1-[[(2S)-1-[[(2R)-1-[[(2S)-1-[[(2S)-1-amino-4-methyl-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]pentanediamide Chemical compound C([C@@H](C(=O)N[C@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(N)=O)NC(=O)[C@@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCCN)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](N)CCCNC(N)=N)C1=CC=CC=C1 QDZOEBFLNHCSSF-PFFBOGFISA-N 0.000 description 22
- 102100024304 Protachykinin-1 Human genes 0.000 description 21
- 101800003906 Substance P Proteins 0.000 description 21
- 208000014674 injury Diseases 0.000 description 16
- 208000027418 Wounds and injury Diseases 0.000 description 15
- 206010048962 Brain oedema Diseases 0.000 description 14
- 230000006931 brain damage Effects 0.000 description 14
- 108010040718 Neurokinin-1 Receptors Proteins 0.000 description 13
- 102000002002 Neurokinin-1 Receptors Human genes 0.000 description 13
- 231100000874 brain damage Toxicity 0.000 description 13
- 208000006752 brain edema Diseases 0.000 description 13
- 239000005557 antagonist Substances 0.000 description 11
- 230000000694 effects Effects 0.000 description 10
- 239000002464 receptor antagonist Substances 0.000 description 10
- 229940044551 receptor antagonist Drugs 0.000 description 10
- 239000003890 substance P antagonist Substances 0.000 description 10
- 230000008499 blood brain barrier function Effects 0.000 description 9
- 210000001218 blood-brain barrier Anatomy 0.000 description 9
- 241001465754 Metazoa Species 0.000 description 8
- 238000011161 development Methods 0.000 description 8
- 230000035699 permeability Effects 0.000 description 8
- 150000001875 compounds Chemical class 0.000 description 7
- 238000000034 method Methods 0.000 description 7
- 102000005962 receptors Human genes 0.000 description 7
- 108020003175 receptors Proteins 0.000 description 7
- 238000002560 therapeutic procedure Methods 0.000 description 7
- 230000002792 vascular Effects 0.000 description 7
- 206010019196 Head injury Diseases 0.000 description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- 206010030113 Oedema Diseases 0.000 description 5
- 230000009286 beneficial effect Effects 0.000 description 5
- 230000015572 biosynthetic process Effects 0.000 description 5
- 230000008569 process Effects 0.000 description 5
- 238000009825 accumulation Methods 0.000 description 4
- 230000001149 cognitive effect Effects 0.000 description 4
- 239000002742 neurokinin 1 receptor antagonist Substances 0.000 description 4
- 230000009467 reduction Effects 0.000 description 4
- 230000000982 vasogenic effect Effects 0.000 description 4
- JLVVSXFLKOJNIY-UHFFFAOYSA-N Magnesium ion Chemical compound [Mg+2] JLVVSXFLKOJNIY-UHFFFAOYSA-N 0.000 description 3
- 230000000903 blocking effect Effects 0.000 description 3
- 208000010877 cognitive disease Diseases 0.000 description 3
- 230000006735 deficit Effects 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 230000002349 favourable effect Effects 0.000 description 3
- 230000006872 improvement Effects 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- 238000001990 intravenous administration Methods 0.000 description 3
- 229910001425 magnesium ion Inorganic materials 0.000 description 3
- 230000007246 mechanism Effects 0.000 description 3
- 230000000926 neurological effect Effects 0.000 description 3
- 108090000765 processed proteins & peptides Proteins 0.000 description 3
- 208000019901 Anxiety disease Diseases 0.000 description 2
- 208000028698 Cognitive impairment Diseases 0.000 description 2
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 2
- 102000003797 Neuropeptides Human genes 0.000 description 2
- 108090000189 Neuropeptides Proteins 0.000 description 2
- 208000002193 Pain Diseases 0.000 description 2
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 2
- 208000030886 Traumatic Brain injury Diseases 0.000 description 2
- 230000036506 anxiety Effects 0.000 description 2
- 230000003851 biochemical process Effects 0.000 description 2
- 210000003169 central nervous system Anatomy 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 230000003111 delayed effect Effects 0.000 description 2
- 229930195712 glutamate Natural products 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 150000002681 magnesium compounds Chemical class 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- CWWARWOPSKGELM-SARDKLJWSA-N methyl (2s)-2-[[(2s)-2-[[2-[[(2s)-2-[[(2s)-2-[[(2s)-5-amino-2-[[(2s)-5-amino-2-[[(2s)-1-[(2s)-6-amino-2-[[(2s)-1-[(2s)-2-amino-5-(diaminomethylideneamino)pentanoyl]pyrrolidine-2-carbonyl]amino]hexanoyl]pyrrolidine-2-carbonyl]amino]-5-oxopentanoyl]amino]-5 Chemical compound C([C@@H](C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)OC)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCCN)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](N)CCCN=C(N)N)C1=CC=CC=C1 CWWARWOPSKGELM-SARDKLJWSA-N 0.000 description 2
- 230000007971 neurological deficit Effects 0.000 description 2
- 230000035790 physiological processes and functions Effects 0.000 description 2
- 238000011321 prophylaxis Methods 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 230000009529 traumatic brain injury Effects 0.000 description 2
- 239000003981 vehicle Substances 0.000 description 2
- 150000005361 3-phenylpyridines Chemical class 0.000 description 1
- MKLQPIYLZMLAER-UHFFFAOYSA-N 4-phenylpyrimidine Chemical class C1=CC=CC=C1C1=CC=NC=N1 MKLQPIYLZMLAER-UHFFFAOYSA-N 0.000 description 1
- LVXOXXGCJHYEOS-UHFFFAOYSA-N 5-phenylpyrimidine Chemical class C1=CC=CC=C1C1=CN=CN=C1 LVXOXXGCJHYEOS-UHFFFAOYSA-N 0.000 description 1
- 208000000044 Amnesia Diseases 0.000 description 1
- 208000031091 Amnestic disease Diseases 0.000 description 1
- YDNKGFDKKRUKPY-JHOUSYSJSA-N C16 ceramide Natural products CCCCCCCCCCCCCCCC(=O)N[C@@H](CO)[C@H](O)C=CCCCCCCCCCCCCC YDNKGFDKKRUKPY-JHOUSYSJSA-N 0.000 description 1
- 108090000312 Calcium Channels Proteins 0.000 description 1
- 102000003922 Calcium Channels Human genes 0.000 description 1
- 208000020401 Depressive disease Diseases 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 101001125071 Homo sapiens Neuromedin-K receptor Proteins 0.000 description 1
- 206010021143 Hypoxia Diseases 0.000 description 1
- 208000019695 Migraine disease Diseases 0.000 description 1
- CRJGESKKUOMBCT-VQTJNVASSA-N N-acetylsphinganine Chemical compound CCCCCCCCCCCCCCC[C@@H](O)[C@H](CO)NC(C)=O CRJGESKKUOMBCT-VQTJNVASSA-N 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- 208000012902 Nervous system disease Diseases 0.000 description 1
- 108010040722 Neurokinin-2 Receptors Proteins 0.000 description 1
- 102100029409 Neuromedin-K receptor Human genes 0.000 description 1
- 206010030124 Oedema peripheral Diseases 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- 102100037342 Substance-K receptor Human genes 0.000 description 1
- 102000003141 Tachykinin Human genes 0.000 description 1
- 102000007124 Tachykinin Receptors Human genes 0.000 description 1
- 108010072901 Tachykinin Receptors Proteins 0.000 description 1
- 208000003443 Unconsciousness Diseases 0.000 description 1
- 206010067275 Vasogenic cerebral oedema Diseases 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- ATNOAWAQFYGAOY-GPTZEZBUSA-J [Na+].[Na+].[Na+].[Na+].Cc1cc(ccc1\N=N\c1ccc2c(cc(c(N)c2c1O)S([O-])(=O)=O)S([O-])(=O)=O)-c1ccc(\N=N\c2ccc3c(cc(c(N)c3c2O)S([O-])(=O)=O)S([O-])(=O)=O)c(C)c1 Chemical compound [Na+].[Na+].[Na+].[Na+].Cc1cc(ccc1\N=N\c1ccc2c(cc(c(N)c2c1O)S([O-])(=O)=O)S([O-])(=O)=O)-c1ccc(\N=N\c2ccc3c(cc(c(N)c3c2O)S([O-])(=O)=O)S([O-])(=O)=O)c(C)c1 ATNOAWAQFYGAOY-GPTZEZBUSA-J 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 230000006986 amnesia Effects 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000003042 antagnostic effect Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 229940106189 ceramide Drugs 0.000 description 1
- ZVEQCJWYRWKARO-UHFFFAOYSA-N ceramide Natural products CCCCCCCCCCCCCCC(O)C(=O)NC(CO)C(O)C=CCCC=C(C)CCCCCCCCC ZVEQCJWYRWKARO-UHFFFAOYSA-N 0.000 description 1
- 230000003727 cerebral blood flow Effects 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- 230000007278 cognition impairment Effects 0.000 description 1
- 230000009514 concussion Effects 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 231100000517 death Toxicity 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- ZUOUZKKEUPVFJK-UHFFFAOYSA-N diphenyl Chemical class C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 210000001951 dura mater Anatomy 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 229960003699 evans blue Drugs 0.000 description 1
- 230000002964 excitative effect Effects 0.000 description 1
- 230000003492 excitotoxic effect Effects 0.000 description 1
- 231100000063 excitotoxicity Toxicity 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 210000001723 extracellular space Anatomy 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 210000001320 hippocampus Anatomy 0.000 description 1
- 210000003016 hypothalamus Anatomy 0.000 description 1
- 230000007954 hypoxia Effects 0.000 description 1
- 208000001286 intracranial vasospasm Diseases 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 159000000003 magnesium salts Chemical class 0.000 description 1
- 238000009115 maintenance therapy Methods 0.000 description 1
- 230000000873 masking effect Effects 0.000 description 1
- 238000010297 mechanical methods and process Methods 0.000 description 1
- 230000005226 mechanical processes and functions Effects 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 206010027599 migraine Diseases 0.000 description 1
- 230000002438 mitochondrial effect Effects 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000036651 mood Effects 0.000 description 1
- 150000002780 morpholines Chemical class 0.000 description 1
- ZSAFRVVCZQRBQS-UHFFFAOYSA-N n-benzyl-2-(4-methylphenyl)pyridine-3-carboxamide Chemical class C1=CC(C)=CC=C1C1=NC=CC=C1C(=O)NCC1=CC=CC=C1 ZSAFRVVCZQRBQS-UHFFFAOYSA-N 0.000 description 1
- 230000008693 nausea Effects 0.000 description 1
- 230000006654 negative regulation of apoptotic process Effects 0.000 description 1
- 230000010807 negative regulation of binding Effects 0.000 description 1
- 210000001577 neostriatum Anatomy 0.000 description 1
- 230000000324 neuroprotective effect Effects 0.000 description 1
- 239000002858 neurotransmitter agent Substances 0.000 description 1
- 230000003957 neurotransmitter release Effects 0.000 description 1
- VVGIYYKRAMHVLU-UHFFFAOYSA-N newbouldiamide Natural products CCCCCCCCCCCCCCCCCCCC(O)C(O)C(O)C(CO)NC(=O)CCCCCCCCCCCCCCCCC VVGIYYKRAMHVLU-UHFFFAOYSA-N 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 150000002927 oxygen compounds Chemical class 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- 150000004885 piperazines Chemical class 0.000 description 1
- 125000003386 piperidinyl group Chemical group 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 150000003180 prostaglandins Chemical class 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 208000020016 psychiatric disease Diseases 0.000 description 1
- 125000004076 pyridyl group Chemical group 0.000 description 1
- SBYHFKPVCBCYGV-UHFFFAOYSA-N quinuclidine Chemical compound C1CC2CCN1CC2 SBYHFKPVCBCYGV-UHFFFAOYSA-N 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000001953 sensory effect Effects 0.000 description 1
- 230000016160 smooth muscle contraction Effects 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 229940066771 systemic antihistamines piperazine derivative Drugs 0.000 description 1
- 108060008037 tachykinin Proteins 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- 230000001960 triggered effect Effects 0.000 description 1
- 229960004799 tryptophan Drugs 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/455—Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/14—Alkali metal chlorides; Alkaline earth metal chlorides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/166—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Inorganic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AUPQ5146A AUPQ514600A0 (en) | 2000-01-18 | 2000-01-18 | Brain injury treatment |
| PCT/AU2001/000046 WO2001052844A1 (en) | 2000-01-18 | 2001-01-18 | Brain, spinal and nerve injury treatment |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| NO20023423D0 NO20023423D0 (no) | 2002-07-17 |
| NO20023423L NO20023423L (no) | 2002-09-16 |
| NO329320B1 true NO329320B1 (no) | 2010-09-27 |
Family
ID=3819274
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO20023423A NO329320B1 (no) | 2000-01-18 | 2002-07-17 | Formulering for behandling av hjerne-, spinal- og nerveskade. |
Country Status (21)
| Country | Link |
|---|---|
| US (5) | US6841551B2 (et) |
| EP (1) | EP1261335B1 (et) |
| JP (1) | JP4794794B2 (et) |
| KR (1) | KR100780119B1 (et) |
| CN (1) | CN1261095C (et) |
| AU (2) | AUPQ514600A0 (et) |
| BR (1) | BR0107695A (et) |
| CA (1) | CA2397723C (et) |
| CZ (1) | CZ20022804A3 (et) |
| DE (1) | DE60139244D1 (et) |
| HK (1) | HK1054872A1 (et) |
| HR (1) | HRP20020593B1 (et) |
| HU (1) | HUP0301920A3 (et) |
| IL (2) | IL150548A0 (et) |
| MX (1) | MXPA02007004A (et) |
| NO (1) | NO329320B1 (et) |
| NZ (2) | NZ519990A (et) |
| RU (1) | RU2276996C2 (et) |
| WO (1) | WO2001052844A1 (et) |
| YU (1) | YU54702A (et) |
| ZA (1) | ZA200205715B (et) |
Families Citing this family (52)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AUPQ514600A0 (en) | 2000-01-18 | 2000-02-10 | James Cook University | Brain injury treatment |
| US20030083345A1 (en) * | 2001-07-10 | 2003-05-01 | Torsten Hoffmann | Method of treatment and/or prevention of brain, spinal or nerve injury |
| RU2543350C2 (ru) | 2003-01-28 | 2015-02-27 | Айронвуд Фармасьютикалз, Инк. | Способы и композиции для лечения желудочно-кишечных расстройств |
| US7772188B2 (en) | 2003-01-28 | 2010-08-10 | Ironwood Pharmaceuticals, Inc. | Methods and compositions for the treatment of gastrointestinal disorders |
| GB0410215D0 (en) * | 2004-05-07 | 2004-06-09 | Lescroart Pol | Nerve damage |
| CN101065014A (zh) * | 2004-09-23 | 2007-10-31 | 亚历山大·米哈洛 | 通过诱导逆适应调节神经递质系统的方法 |
| US20080045610A1 (en) * | 2004-09-23 | 2008-02-21 | Alexander Michalow | Methods for regulating neurotransmitter systems by inducing counteradaptations |
| BRPI0606187A2 (pt) | 2005-02-25 | 2009-06-09 | Hoffmann La Roche | comprimidos com capacidade de dispersão da substáncia do fármaco melhorada |
| WO2006110118A1 (fr) * | 2005-04-15 | 2006-10-19 | Victor Pavlovich Kutnyak | Produit cytoprotecteur |
| US20060239921A1 (en) * | 2005-04-26 | 2006-10-26 | Novadaq Technologies Inc. | Real time vascular imaging during solid organ transplant |
| US8185176B2 (en) | 2005-04-26 | 2012-05-22 | Novadaq Technologies, Inc. | Method and apparatus for vasculature visualization with applications in neurosurgery and neurology |
| US10231624B2 (en) * | 2005-08-10 | 2019-03-19 | Nov Adaq Technologies Ulc | Intra-operative head and neck nerve mapping |
| US20070122344A1 (en) * | 2005-09-02 | 2007-05-31 | University Of Rochester Medical Center Office Of Technology Transfer | Intraoperative determination of nerve location |
| US20070154448A1 (en) * | 2005-11-22 | 2007-07-05 | Ted Reid | Methods and compositions using Substance P to promote wound healing |
| US8945623B2 (en) * | 2006-05-03 | 2015-02-03 | Warsaw Orthopedic, Inc. | Compositions comprising biomembrane sealing agent for treatment of neuronal injury, and methods of use |
| US20080161744A1 (en) * | 2006-09-07 | 2008-07-03 | University Of Rochester Medical Center | Pre-And Intra-Operative Localization of Penile Sentinel Nodes |
| US20080241121A1 (en) * | 2007-04-02 | 2008-10-02 | Daniela Salvemini | Inhibitors of the ceramide metabolic pathway as adjuncts to opiates for pain |
| US20100086543A1 (en) * | 2007-04-02 | 2010-04-08 | Saint Louis University | Compositions and methods for treating conditions associated with ceramide biosynthesis |
| US8969514B2 (en) | 2007-06-04 | 2015-03-03 | Synergy Pharmaceuticals, Inc. | Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases |
| EA020466B1 (ru) | 2007-06-04 | 2014-11-28 | Синерджи Фармасьютикалз Инк. | Агонисты гуанилатциклазы, пригодные для лечения желудочно-кишечных нарушений, воспаления, рака и других заболеваний |
| AU2008278273A1 (en) * | 2007-07-19 | 2009-01-22 | Adelaide Research & Innovation Pty Ltd | Method for reducing intracranial pressure |
| US8406860B2 (en) | 2008-01-25 | 2013-03-26 | Novadaq Technologies Inc. | Method for evaluating blush in myocardial tissue |
| US10219742B2 (en) | 2008-04-14 | 2019-03-05 | Novadaq Technologies ULC | Locating and analyzing perforator flaps for plastic and reconstructive surgery |
| US20090263507A1 (en) * | 2008-04-18 | 2009-10-22 | Warsaw Orthopedic, Inc. | Biological markers and response to treatment for pain, inflammation, neuronal or vascular injury and methods of use |
| ES2671710T3 (es) | 2008-05-02 | 2018-06-08 | Novadaq Technologies ULC | Métodos para la producción y uso de eritrocitos cargados con sustancias para la observación y el tratamiento de la hemodinámica microvascular |
| EP2810951B1 (en) | 2008-06-04 | 2017-03-15 | Synergy Pharmaceuticals Inc. | Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders |
| ES2624828T3 (es) | 2008-07-16 | 2017-07-17 | Synergy Pharmaceuticals Inc. | Agonistas de la guanilato ciclasa útiles para el tratamiento de trastornos gastrointestinales, inflamación, cáncer y otros |
| WO2018129556A1 (en) | 2017-01-09 | 2018-07-12 | Ardelyx, Inc. | Compounds and methods for inhibiting nhe-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders |
| CN103819403B (zh) | 2008-12-31 | 2017-01-04 | 阿德利克斯公司 | 用于治疗与体液潴留或盐超负荷有关的病症和胃肠道病症的化合物和方法 |
| US8852566B2 (en) * | 2009-03-26 | 2014-10-07 | Warsaw Orthopedic, Inc. | Compositions and methods for preferential distribution of active agents to injury sites |
| US10492671B2 (en) | 2009-05-08 | 2019-12-03 | Novadaq Technologies ULC | Near infra red fluorescence imaging for visualization of blood vessels during endoscopic harvest |
| US9616097B2 (en) | 2010-09-15 | 2017-04-11 | Synergy Pharmaceuticals, Inc. | Formulations of guanylate cyclase C agonists and methods of use |
| JP6154135B2 (ja) * | 2010-12-03 | 2017-06-28 | 国立大学法人 岡山大学 | 外傷性神経障害治療剤 |
| WO2012125020A1 (en) * | 2011-03-14 | 2012-09-20 | N.V. Nutricia | Method for treating neurotrauma |
| WO2013190391A2 (en) | 2012-06-21 | 2013-12-27 | Novadaq Technologies Inc. | Quantification and analysis of angiography and perfusion |
| AU2013304812B2 (en) | 2012-08-21 | 2016-06-09 | Ardelyx, Inc. | Compounds and methods for inhibiting NHE-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders |
| US10376481B2 (en) | 2012-08-21 | 2019-08-13 | Ardelyx, Inc. | Compounds and methods for inhibiting NHE-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders |
| CA2905435A1 (en) | 2013-03-15 | 2014-09-25 | Synergy Pharmaceuticals Inc. | Compositions useful for the treatment of gastrointestinal disorders |
| CA2905438A1 (en) | 2013-03-15 | 2014-09-25 | Synergy Pharmaceuticals Inc. | Agonists of guanylate cyclase and their uses |
| KR20230132619A (ko) | 2013-04-12 | 2023-09-15 | 알데릭스, 인코포레이티드 | Nhe3-결합 화합물 및 포스페이트 수송을 저해하는 방법 |
| PT3004138T (pt) | 2013-06-05 | 2024-06-18 | Bausch Health Ireland Ltd | Agonistas ultrapuros de guanilato ciclase c, método de produção e utilização dos mesmos |
| RU2674653C2 (ru) * | 2013-07-02 | 2018-12-12 | Юстрэлиз Фармасьютикалз Лимитед (Трейдинг Эз Пресшура Нейро) | Способ предотвращения и/или лечения хронической травматической энцефалопатии - ii |
| EP3016659A4 (en) * | 2013-07-02 | 2017-03-15 | Eustralis Pharmaceuticals Limited (Trading as Pressura Neuro) | Method for preventing and/or treating chronic traumatic encephalopathy-iii |
| EP3016658A4 (en) * | 2013-07-02 | 2017-03-15 | Eustralis Pharmaceuticals Limited (Trading as Pressura Neuro) | Method for preventing and/or treating chronic traumatic encephalopathy-iv |
| CN105451727B (zh) * | 2013-07-02 | 2019-04-23 | 尤斯特拉里斯制药有限公司（以普雷舒拉纽罗作为商号） | 用于预防和/或治疗i型慢性创伤性脑病的方法 |
| CN107209118B (zh) | 2014-09-29 | 2021-05-28 | 史赛克欧洲运营有限公司 | 在自体荧光存在下生物材料中目标荧光团的成像 |
| EP3915467A1 (en) | 2014-10-09 | 2021-12-01 | Novadaq Technologies ULC | Quantification of absolute blood flow in tissue using fluorescence-mediated photoplethysmography |
| AU2018205400B2 (en) | 2017-01-09 | 2022-07-14 | Ardelyx, Inc. | Compounds useful for treating gastrointestinal tract disorders |
| EP3565811A1 (en) | 2017-01-09 | 2019-11-13 | Ardelyx, Inc. | Inhibitors of nhe-mediated antiport |
| WO2018145193A1 (en) | 2017-02-10 | 2018-08-16 | Novadaq Technologies ULC | Open-field handheld fluorescence imaging systems and methods |
| KR20220050956A (ko) * | 2019-08-23 | 2022-04-25 | 유스트랄리스 파마슈티칼스 리미티드 (트레이딩 애즈 프레스수라 뉴로) | 치료 방법 및 이의 용도 |
| WO2021202286A1 (en) * | 2020-03-30 | 2021-10-07 | Dignify Therapeutics, Llc | Compositions and methods for treating autonomic dysreflexia |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4481139A (en) * | 1983-04-13 | 1984-11-06 | Board Of Regents, The University Of Texas System | Peptide antagonists of substance P |
| US4985896A (en) * | 1985-03-29 | 1991-01-15 | Canon Kabushiki Kaisha | Laser driving device |
| US4981744A (en) * | 1990-04-24 | 1991-01-01 | Swank Michael W | Non-planar expandable honeycomb structure |
| NZ255721A (en) | 1992-08-13 | 1997-06-24 | Warner Lambert Co | Hetarylmethoxy carbonyl substituted tryptophan amides, esters, analogues and pharmaceutical compositions thereof |
| US5610165A (en) * | 1994-02-17 | 1997-03-11 | Merck & Co., Inc. | N-acylpiperidine tachykinin antagonists |
| US5744482A (en) * | 1994-10-05 | 1998-04-28 | Eli Lilly And Company | Serotonin agonist in combination with a tachykinin receptor antagonist in the treatment or prevention of migraine |
| US5998444A (en) * | 1995-10-24 | 1999-12-07 | Zeneca Ltd. | Piperidinyl compounds as NK1 or NK2 antagonists |
| IL116249A (en) * | 1994-12-12 | 2003-07-06 | Pfizer | Nk-1 receptor antagonists for the treatment of neuronal damage and stroke |
| WO1996024353A1 (en) * | 1995-02-10 | 1996-08-15 | Eli Lilly And Company | Methods of treating or preventing psychiatric disorders |
| US5795894A (en) * | 1995-05-02 | 1998-08-18 | Schering Corporation | Piperazino derivatives as neurokinn antagonists |
| US5990125A (en) | 1996-01-19 | 1999-11-23 | Pfizer Inc. | NK-1 receptor antagonists for the treatment of cancer |
| WO1997038701A1 (en) * | 1996-04-12 | 1997-10-23 | Neotech Medical Innovations In | Composition and method for the treatment of premenstrual syndrome |
| US5977104A (en) * | 1996-12-02 | 1999-11-02 | Merck Sharp & Dohme Ltd. | Use of NK-1 receptor antagonists for treating bipolar disorders |
| EP1017395A4 (en) * | 1997-08-28 | 2003-06-04 | Merck & Co Inc | METHOD FOR TREATING THE PRESENTIAL OR LATE-PHASE SYNDROME |
| GB9812662D0 (en) | 1998-06-11 | 1998-08-12 | Merck Sharp & Dohme | Therapeutic use |
| WO2000050398A2 (en) | 1999-02-24 | 2000-08-31 | F. Hoffmann-La Roche Ag | Phenyl- and pyridinyl derivatives as neurokinin 1 antagonists |
| AU772446B2 (en) | 1999-02-24 | 2004-04-29 | F. Hoffmann-La Roche Ag | 3-phenylpyridine derivatives and their use as NK-1 receptor antagonists |
| EP1035115B1 (en) * | 1999-02-24 | 2004-09-29 | F. Hoffmann-La Roche Ag | 4-Phenylpyridine derivatives and their use as NK-1 receptor antagonists |
| US6291465B1 (en) | 1999-03-09 | 2001-09-18 | Hoffmann-La Roche Inc. | Biphenyl derivatives |
| US6274588B1 (en) | 1999-05-31 | 2001-08-14 | Hoffmann-La Roche Inc. | 4-phenyl-pyrimidine derivatives |
| JO2308B1 (en) | 1999-05-31 | 2005-09-12 | اف. هوفمان- لاروش أيه جي | Derivatives of phenylpyrmidine |
| GB9923748D0 (en) * | 1999-10-07 | 1999-12-08 | Glaxo Group Ltd | Chemical compounds |
| AUPQ514600A0 (en) | 2000-01-18 | 2000-02-10 | James Cook University | Brain injury treatment |
| US6479433B1 (en) * | 2000-10-02 | 2002-11-12 | Smithers-Oasis Company | Polyurethane foam composites for grower applications and related methods |
-
2000
- 2000-01-18 AU AUPQ5146A patent/AUPQ514600A0/en not_active Abandoned
-
2001
- 2001-01-18 KR KR1020027009218A patent/KR100780119B1/ko not_active IP Right Cessation
- 2001-01-18 RU RU2002121640/15A patent/RU2276996C2/ru not_active IP Right Cessation
- 2001-01-18 CA CA2397723A patent/CA2397723C/en not_active Expired - Fee Related
- 2001-01-18 HU HU0301920A patent/HUP0301920A3/hu unknown
- 2001-01-18 AU AU26560/01A patent/AU782799B2/en not_active Expired
- 2001-01-18 US US10/181,323 patent/US6841551B2/en not_active Expired - Fee Related
- 2001-01-18 MX MXPA02007004A patent/MXPA02007004A/es active IP Right Grant
- 2001-01-18 CN CNB018037208A patent/CN1261095C/zh not_active Expired - Fee Related
- 2001-01-18 DE DE60139244T patent/DE60139244D1/de not_active Expired - Fee Related
- 2001-01-18 BR BR0107695-7A patent/BR0107695A/pt not_active IP Right Cessation
- 2001-01-18 IL IL15054801A patent/IL150548A0/xx unknown
- 2001-01-18 JP JP2001552892A patent/JP4794794B2/ja not_active Expired - Fee Related
- 2001-01-18 YU YU54702A patent/YU54702A/sh unknown
- 2001-01-18 NZ NZ519990A patent/NZ519990A/en not_active IP Right Cessation
- 2001-01-18 WO PCT/AU2001/000046 patent/WO2001052844A1/en active IP Right Grant
- 2001-01-18 CZ CZ20022804A patent/CZ20022804A3/cs unknown
- 2001-01-18 NZ NZ534278A patent/NZ534278A/en not_active IP Right Cessation
- 2001-01-18 EP EP01901048A patent/EP1261335B1/en not_active Expired - Lifetime
-
2002
- 2002-07-02 IL IL150548A patent/IL150548A/en not_active IP Right Cessation
- 2002-07-16 HR HR20020593A patent/HRP20020593B1/xx not_active IP Right Cessation
- 2002-07-17 NO NO20023423A patent/NO329320B1/no not_active IP Right Cessation
- 2002-07-17 ZA ZA200205715A patent/ZA200205715B/en unknown
-
2003
- 2003-10-14 HK HK03107353A patent/HK1054872A1/xx not_active IP Right Cessation
-
2004
- 2004-12-21 US US11/017,978 patent/US20050107380A1/en not_active Abandoned
-
2009
- 2009-06-01 US US12/475,627 patent/US9186404B2/en not_active Expired - Lifetime
-
2015
- 2015-10-13 US US14/882,084 patent/US20160030474A1/en not_active Abandoned
-
2017
- 2017-09-25 US US15/714,819 patent/US10201568B2/en not_active Expired - Lifetime
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO329320B1 (no) | Formulering for behandling av hjerne-, spinal- og nerveskade. | |
| Meckes et al. | Terpenoids isolated from Psidium guajava hexane extract with depressant activity on central nervous system | |
| US20210100755A1 (en) | Use of the phytocannabinoid cannabidivarin (cbdv) in the treatment of epilepsy | |
| Baraka et al. | A comparison of epidural tramadol and epidural morphine for postoperative analgesia | |
| Dohi et al. | Angiotensin blockade or calcium antagonists improve endothelial dysfunction in hypertension: studies in perfused mesenteric resistance arteries | |
| JP2002532392A (ja) | エキソ−ｓ−メカミラミン製剤および治療におけるその使用 | |
| DE60111025T2 (de) | Verwendung von Topiramat zur Behandlung und Diagnostizierung von Atemstörungen während des Schlafens und Mittel zur Durchführung der Behandlung und Diagnose | |
| Wilker | Theories related to physical dependence | |
| Maggi et al. | Nitric oxide is the mediator of tachykinin NK3 receptor-induced relaxation in the circular muscle of the guinea-pig ileum | |
| Huang et al. | Cocaine-induced cerebral vascular damage can be ameliorated by Mg2+ in rat brain | |
| Zajonc et al. | Vertigo and motion sickness. Part I: vestibular anatomy and physiology | |
| Diz et al. | Acute depressor actions of angiotensin II in the nucleus of the solitary tract are mediated by substance P | |
| DE69725613T2 (de) | Neue therapeutische verwendung eines thienylcyclohexylaminderivates | |
| DE60305018T2 (de) | Citalopram zur behandlung von bluthochdruck | |
| DE10318714B4 (de) | Wirkstoff-Kombinationen und Therapien zur Bekämpfung des Alkoholmissbrauches | |
| Cirillo et al. | Pharmacology of MEN 11467: a potent new selective and orally-effective peptidomimetic tachykinin NK1 receptor antagonist | |
| Yen et al. | Effects of 4-aminopyridine on cat blood pressure in relation to the sympathetic nervous system | |
| Kiss et al. | The role of magnesium in the supposed mechanism of anaesthesia | |
| PL203468B1 (pl) | Preparat do do zylnego lub domi esniowego leczenia uszkodzenia mózgu, rdzenia kr egowego i nerwów | |
| Squires | REGIONAL HETEROGENEITY OF BENZODIAZEPINE BINDING SITES IN RAT BRAIN | |
| Cooke | MINERS'NYSTAGMUS | |
| Kaplan et al. | Transient Blindness during Pralidoxime Administration for Organophosphate Toxicity | |
| Cehetheamel | ND~~ Bmax N Bmrax |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MM1K | Lapsed by not paying the annual fees |